Maze Therapeutics' (MAZE) development strategy using genetic validation is seen as promising in terms of its target identification strategy and application to the nephrology and metabolic disease segments, Wedbush Securities said in a note Tuesday.
The firm said the Maze Compass platform using genetic variant analysis to name and validate potential targets is "impressive."
Wedbush added that competitor data is a source of external validation, which creates a degree of derisking related to the company's lead assets of MZE829 in APOL1 kidney disease and MZE728 in phenylketonuria.
"Combining multiple near-term catalysts with cash runway into [H2 of 2027], and we see favorable risk/reward for MAZE shares as the stock trades near a [roughly $500 million] valuation," the firm said.
Wedbush initiated coverage on the company with an outperform rating and $17 price target.
Shares of Maze Therapeutics were 5% in recent trading.
Price: 12.73, Change: +0.61, Percent Change: +5.03
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.